Is a complete NBIX research report available?

No complete published report is available for Neurocrine Biosciences, Inc. (NBIX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

NBIX Stock Analysis, Forecast & Valuation

Market cap	18.2B
Revenue (ttm)	3.1B
Net income (ttm)	668.6M
EPS (ttm)	$6.50
Shares out	100.5M
P/E (trailing)	27.8x
P/E (forward)	17.8x
Volume	1,072,192
Beta	0.39

Price target	$202	+11.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All NBIX indicators

Market & fundamental data

Available fields

273

Groups with data

Currency

USD

Showing 273 of 273 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000914475
Company name	Neurocrine Biosciences, Inc.
Country	United States
Country code	US
Cusip	64125C109
Employees	2,000
Employees Change	200%
Employees Change Percent	11.11
Enterprise value	$17.3B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Industry PE	90.42
Industry PE Fwd	14.46
IPO Date	1996-05-23
Isin	US64125C1099
Last refreshed	2026-07-30
Market cap	$18.2B
Market cap category	Large-Cap
Price	$181
Price currency	USD
Rev Per Employee	1,551,200x
Sector	Healthcare
Sector PE	45.64
Sector PE Fwd	24.21
Sic	2836
Symbol	NBIX
Website	https://www.neurocrine.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	3.68%
EV Earnings	25.91x
EV Sales Forward	4.31x
EV/EBIT	21.96x
EV/EBITDA	21.16x
EV/FCF	20.84x
EV/Sales	5.58x
FCF yield	4.57%
Forward P/E	17.76x
P/B ratio	5.34x
P/E ratio	27.8x
P/S ratio	5.86x
PE Ratio10 Y	154.83x
PE Ratio3 Y	38.65x
PE Ratio5 Y	94.5x
PEG ratio	0.37x
PS Forward	4.52x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	25.43%
EBITDA Margin	26.39%
FCF margin	26.8%
Gross margin	64.37%
Gross Profit	$2B
Gross Profit Growth	29.51%
Gross Profit Growth Q	68.05%
Gross Profit Growth3 Y	23.11%
Gross Profit Growth5 Y	21.81%
Net Income	$668.6M
Net Income Growth	118.64%
Net Income Growth Q	2,405.06%
Net Income Growth Quarters	4%
Net Income Growth Years	4%
Net Income Growth3 Y	118.61%
Net Income Growth5 Y	10.71%
Pretax Margin	30.22%
Profit Margin	21.55%
Profit Per Employee	$334,300
Profitable Quarters	$12
Profitable Years	8
ROA	11.62
Roa5y	8.57
ROCE	19.36
ROE	22.5
Roe5y	12.08
ROIC	23.74
Roic5y	20.75

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	13.68%
Cagr15y	23.12%
Cagr1y	35.24%
Cagr20y	15.94%
Cagr3y	20.72%
Cagr5y	14%
EPS Growth	119.9
EPS Growth Q	2,310.5
EPS Growth Quarters	4
EPS Growth Years	4
EPS Growth3 Y	115.8
EPS Growth5 Y	9.71
FCF Growth	68.9%
FCF Growth Q	152.68%
FCF Growth3 Y	51.88%
FCF Growth5 Y	25.58%
OCF Growth	62.99%
OCF Growth Q	125%
OCF Growth3 Y	50.24%
OCF Growth5 Y	25.24%
Revenue Growth	28.59x
Revenue Growth Q	42.25x
Revenue Growth Quarters	19x
Revenue Growth Years	9x
Revenue Growth3 Y	24.74x
Revenue Growth5 Y	24.3x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.72
Assets	$4.9B
Cash	$1.3B
Current Assets	$2.4B
Current Liabilities	$831.7M
Debt	$463.5M
Debt EBITDA	$0.57
Debt Equity	$0.14
Debt FCF	$0.56
Equity	$3.4B
Liabilities	$1.5B
Long Term Assets	$2.5B
Long Term Liabilities	$667.1M
Net Cash	$852.7M
Net Cash By Market Cap	$4.69
Net Cash Growth	89.32%
Net Debt EBITDA	$-1.04
Net Debt Equity	$-0.25
Net Debt FCF	$-1.03
Tangible Book Value	$3.4B
Tangible Book Value Per Share	$33.87
WACC	6.21

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.93
Inventory Turnover	17.89
Net Working Capital	$345.5M
Quick ratio	2.51
Working Capital	$1.6B
Working Capital Turnover	$2.28

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.68%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	260.5%
1Y total return	35.21%
200-day SMA	145.5
3Y total return	75.95%
50-day SMA	166.5
50-day SMA vs 200-day SMA	50over200
5Y total return	92.49%
All Time High	183.5
All Time High Change	-1.48%
All Time High Date	2026-07-29
All Time Low	1.94
All Time Low Change	9,219.07%
All Time Low Date	2009-11-30
ATR	4.86
Beta	0.39
Beta1y	0.63
Beta2y	0.63
Ch YTD	27.47
High	183.5
High52	183.5
High52 Date	2026-07-29
High52ch	-1.48%
Low	180
Low52	122.1
Low52 Date	2026-02-12
Low52ch	48.02%
Ma50ch	8.56%
Price vs 200-day SMA	24.24%
RSI	62.5
RSI Monthly	69.82
RSI Weekly	70.33
Sharpe ratio	0.98x
Sortino ratio	1.62
Total Return	0.68%
Tr YTD	27.47
Tr15y	2,165.54%
Tr1m	7.28%
Tr1w	4.69%
Tr3m	41.11%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	28
Analyst Count Top	25
Analyst Price Target Top	$197
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$2.1
Earnings EPS Estimate Growth	27.27
Earnings Revenue Estimate	876,588,096x
Earnings Revenue Estimate Growth	27.5x
Operating Income	$798.8M
Operating Income Growth	54.99
Operating Income Growth Q	684.8
Operating Income Growth3 Y	42.58
Operating Income Growth5 Y	21.63
Operating margin	25.75
Price target	$202
Price Target Change	$11.83
Price Target Change Top	$8.99

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	99,295,548%
Float Percent	98.75%
Shares Insiders	1.17%
Shares Institutions	102.75%
Shares Out	100,549,983
Shares Qo Q	-0.29%
Shares Yo Y	-0.68%
Short Float	5.37%
Short Ratio	4.38
Short Shares	5.31

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$609M
Adjusted OCF	641,400,000
Average Volume	1,099,680.9x
Bv Per Share	33.87
CAPEX	$-32.4M
Ch10y	260.5
Ch15y	2,165.5
Ch1m	7.28
Ch1w	4.69
Ch1y	35.21
Ch20y	1,825.3
Ch3m	41.11
Ch3y	75.95
Ch5y	92.49
Ch6m	34.26
Change	-1.12%
Change From Open	-0.66
Close	182.8
Days Gap	-0.45
Depreciation Amortization	29,800,000
Dollar Volume	193,841,591.7
Earnings Date	2026-07-30
Earnings Time	amc
EBIT	$788.9M
EBITDA	$818.7M
EPS	$6.5
F Score	6
FCF	$831.3M
FCF EV Yield	4.8x
FCF Per Share	$8.27
Financing CF	-6,500,000
Fiscal Year End	December
Founded	1,992
Graham Number	70.39533
Graham Upside	-61.06
Income Tax	$268.9M
Investing CF	-784,800,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-07-30
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-11
Lynch Fair Value	$69.64
Lynch Upside	-61.48
Ma150	145.4
Ma150ch	24.34%
Ma20	175.2
Ma20ch	3.17%
Net CF	72,400,000
Next Earnings Date	2026-10-27
Open	182
Optionable	Yes
P FCF Ratio	21.87
P FCF Ratio SBC	29.85
P OCF Ratio	21.05
P OCF Ratio SBC	28.34
Position In Range	22.57
Post Close	180.8
Postmarket Change Percent	-0.44
Postmarket Price	$180
Ppne	538,000,000
Price Date	2026-07-29
Price EBITDA	$22.2
Ptbv Ratio	5.33
Relative Volume	0.98x
Revenue	3,102,400,000x
SBC By Revenue	7.17x
Share Based Comp	222,300,000
Tax By Revenue	8.67x
Tax Rate	28.68%
Tr20y	1,825.35%
Tr6m	34.26%
Us State	California
Volume	1,072,192
Z Score	6.99

Neurocrine Biosciences, Inc. (NBIX)

Coverage state: Market snapshot only — no published research

Generate the first NBIX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · NBIX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NBIX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on NBIX

Frequently asked questions